PatientsVille.com Logo

BONE DENSITY DECREASED and RECLAST

PatientsVille

BONE DENSITY DECREASED Symptoms and Causes

What is primary ovarian insufficiency (POI)?

Primary ovarian insufficiency (POI), also known as premature ovarian failure, happens when a woman's ovaries stop working normally before she is 40.

Many women naturally experience reduced fertility when they are about 40 years old. They may start getting irregular menstrual periods as they transition to menopause. For women with POI, irregular periods and reduced fertility start before the age of 40. Sometimes it can start as early as the teenage years.

POI is different from premature menopause. With premature menopause, your periods stop before age 40. You can no longer get pregnant. The cause can be natural or it can be a disease, surgery, chemotherapy, or radiation. With POI, some women still have occasional periods. They may even get pregnant. In most cases of POI, the cause is unknown.

What causes primary ovarian insufficiency (POI)?

In about 90 percent of cases, the exact cause of POI is unknown.

Research shows that POI is related to problems with the follicles. Follicles are small sacs in your ovaries. Your eggs grow and mature inside them. One type of follicle problem is that you run out of working follicles earlier than normal. Another is that the follicles are not working properly. In most cases, the cause of the follicle problem is unknown. But sometimes the cause may be

  • Genetic disorders such as Fragile X syndrome and Turner syndrome
  • A low number of follicles
  • Autoimmune diseases, including thyroiditis and Addison disease
  • Chemotherapy or radiation therapy
  • Metabolic disorders
  • Toxins, such as cigarette smoke, chemicals, and pesticides
Who is at risk for for primary ovarian insufficiency (POI)?

Certain factors can raise a woman's risk of POI:

  • Family history. Women who have a mother or sister with POI are more likely to have it.
  • Genes. Some changes to genes and genetic conditions put women at higher risk for POI. For example, women Fragile X syndrome or Turner syndrome are at higher risk.
  • Certain diseases, such as autoimmune diseases and viral infections
  • Cancer treatments, such as chemotherapy and radiation therapy
  • Age. Younger women can get POI, but it becomes more common between the ages of 35-40.
What are the symptoms of primary ovarian insufficiency (POI)?

The first sign of POI is usually irregular or missed periods. Later symptoms may be similar to those of natural menopause:

  • Hot flashes
  • Night sweats
  • Irritability
  • Poor concentration
  • Decreased sex drive
  • Pain during sex
  • Vaginal dryness

For many women with POI, trouble getting pregnant or infertility is the reason they go to their health care provider.

What other problems can primary ovarian insufficiency (POI) cause?

Since POI causes you to have lower levels of certain hormones, you are at greater risk for other health conditions, including

  • Anxiety and depression. Hormonal changes caused by POI can contribute to anxiety or lead to depression.
  • Dry eye syndrome and eye surface disease. Some women with POI have one of these eye conditions. Both can cause discomfort and may lead to blurred vision. If not treated, these conditions can cause permanent eye damage.
  • Heart disease. Lower levels of estrogen can affect the muscles lining the arteries and can increase the buildup of cholesterol in the arteries. These factors increase your risk of atherosclerosis (hardening of the arteries).
  • Infertility.
  • Low thyroid function. This problem also is called hypothyroidism. The thyroid is a gland that makes hormones that control your body's metabolism and energy level. Low levels thyroid hormones can affect your metabolism and can cause very low energy, mental sluggishness, and other symptoms.
  • Osteoporosis. The hormone estrogen helps keep bones strong. Without enough estrogen, women with POI often develop osteoporosis. It is a bone disease that causes weak, brittle bones that are more likely to break.
How is primary ovarian insufficiency (POI) diagnosed?

To diagnose POI, your health care provider may do

  • A medical history, including asking whether you have relatives with POI
  • A pregnancy test, to make sure that you are not pregnant
  • A physical exam, to look for signs of other disorders which could be causing your symptoms
  • Blood tests, to check for certain hormone levels. You may also have a blood test to do a chromosome analysis. A chromosome is the part of a cell that contains genetic information.
  • A pelvic ultrasound, to see whether or not the ovaries are enlarged or have multiple follicles
How is primary ovarian insufficiency (POI) treated?

Currently, there is no proven treatment to restore normal function to a woman's ovaries. But there are treatments for some of the symptoms of POI. There are also ways to lower your health risks and treat the conditions that POI can cause:

  • Hormone replacement therapy (HRT).HRT is the most common treatment. It gives your body the estrogen and other hormones that your ovaries are not making. HRT improves sexual health and decreases the risks for heart disease and osteoporosis. You usually take it until about age 50; that's about the age when menopause usually begins.
  • Calcium and vitamin D supplements. Because women with POI are at higher risk for osteoporosis, you should take calcium and vitamin D every day.
  • In vitro fertilization (IVF). If you have POI and you wish to become pregnant, you may consider trying IVF.
  • Regular physical activity and a healthy body weight.Getting regular exercise and controlling your weight can lower your risk for osteoporosis and heart disease.
  • Treatments for associated conditions. If you have a condition that is related to POI, it is important to treat that as well. Treatments may involve medicines and hormones.

NIH: National Institute of Child Health and Human Development

Check out the latest treatments for BONE DENSITY DECREASED

BONE DENSITY DECREASED treatment research studies

RECLAST clinical trials, surveys and public health registries


Find Drug Side Effect reports



RECLAST Side Effects

Arthralgia (599)
Pain (418)
Myalgia (402)
Headache (341)
Bone Pain (334)
Pyrexia (332)
Influenza Like Illness (315)
Nausea (272)
Chills (241)
Asthenia (234)
Fatigue (233)
Back Pain (228)
Pain In Extremity (213)
Dizziness (181)
Dyspnoea (177)
Chest Pain (163)
Vomiting (163)
Malaise (141)
Gait Disturbance (136)
Diarrhoea (128)
Death (122)
Pain In Jaw (121)
Muscle Spasms (112)
Feeling Abnormal (101)
Abasia (99)
Musculoskeletal Pain (99)
Oedema Peripheral (98)
Blood Creatinine Increased (95)
Fall (89)
Joint Swelling (84)
Neck Pain (83)
Dehydration (79)
Confusional State (76)
Muscular Weakness (73)
Blood Pressure Increased (69)
Abdominal Pain (67)
Renal Failure Acute (67)
Musculoskeletal Stiffness (66)
Paraesthesia (66)
Hypoaesthesia (65)
Decreased Appetite (63)
Insomnia (60)
Erythema (59)
Eye Pain (58)
Chest Discomfort (57)
Atrial Fibrillation (56)
Activities Of Daily Living Impaired (55)
Hypocalcaemia (54)
Syncope (53)
Osteonecrosis (52)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I just had the infusion two days ago (1/19/10) and was surprised with the intensity of muscle pain the day after the treatment. My pain was localized to my rib cage, neck, shoulders and upper back. In addition I was very fatiqued...slept most of

"Association does not equal causation": posters seem to assume that any symptom occurring within a year of the Reclast infusion is caused by Reclast (just noticing that, and wondering whether the manufacturer needs to do a better jo

<span style='color: #808080;'>i was very unsure about reclast but the specialist was very pushie about me tring it,when i read up on it everything negative ( as far as reviews) my doc said don't go by reviews.aftre 2 mths i

Tell women not to take this drug. I for see huge lawsuits in the future. I may not live that long but it will happen! I was told to report to the hospital for my infusion. No one told me mu

<span style='color: #808080;'>si vous prenez le medrol 16 mg mangez des dattes et des bananes qui sont riches en potassium et n'oubliez pas de faire des analyses de temps en temps , une chute de potassium pourrait&ecirc;tre&nb

<strong></strong><span style='color: #808080;'>I had my first Reclast infusion last Thursday morning. I am a nurse so am on my feet a lot and at work Thursday evening I started having pain across the back of my

12 hours after Reclast IV, had fever, chills, pain in stomach, dizziness, headache - lasted 12 hours on and off - scary.

2 months after injection . I want to say I was extremely ill the day, about 10 hours afterwards , I got my Iv infusion of this medication . About 10 hours after the IV infusion I became very sick , Flu like symptoms , 103.6 temperture , thought

About 6 weeks after I got Reclast I got pains in my groin and hip. Is that a coincidence or is it possible to have these symptoms so long after the infusions. It is now 5 months and I now have pain in both hips, back and tingling in my feet and one

After my first (and last) experience with this drug, on January 5, 2011, I'm in pain. My back,my shoulder, my neck, my chest hurt. I'm taking pain killers to deal with the pain, but its not enough. Did someone had a better way ease the pain?

Calculate the moles of calcium carbonate present in a 25.00 mL sample of a standard solution, assuming the standard is known to have a hardness of 105 ppm (hardness due to CaCO3 ). You can assume that the density

When I press down on my stomach, in the lower right side in the pelvic region it hurts. Right by my hip bone. This has been going on for about a week. Could this be really bad? Im scared that I could be pregnant. but i dont think

<span style='color: #808080;'><b>i was given a flu shot on 11/18/10 the medical asst did the injection higher than i have ever had in the past. she injected right on the bone. the pain i have is horrible. i had an exray. (no foreign body)

1st day was hell, had about every side effect in the book. 2nd day was better, side effects decreased greatly 5th day is going well so far- feeling a little 'edgy &amp; apprehensive' but better than the alternative

After 10 days of taking Aclasta serum 5mg i had all the side effects and after 10 days i still have chills and bone pain, what should i do? By the way im having a blood test tomorrow to know about the kidney,liver and glucose. so what should i do??

After 2 and half months of taking boniva i devoped severe shoulder pain that cause tendonitis and bursitis and abnormal bone formation and will have to have surgery now to inprove my pain i have been in severe pain for 5 months now boniva side eff

After a few weeks on Piascledine, knee and back pain decreased considerably with no side effects noted. Not perfect, but much better. I was walking like an old man.

After the first gardisil shot i started getting a redish brown line following my hip bone then it spread to my upper stomach, just solid around the abdominal area. After i got a small itchy red dot on my back and about a month later it turned into a

Age 58, stage 1 breast cancer a year ago. double mastecomy, by choice. chemo...started aromasin in October 2008. had a bone denstity test in September 2008 and started fosamax.... had another bone denstity test in April 2009 and before the results

Am sorry if my english is bad::::::: my mother hadlymphoma in bone marrors docter give mabthera 600mg is that good for him

BONE DENSITY DECREASED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting The Use of Zoledronic Acid to Complex Regional Pain Syndrome
Condition: Complex Regional Pain Syndromes
Interventions: Drug: Zoledronic acid;   Drug: Placebo
Outcome Measures: Pain measured on Visual Analog Scale;   Lower Limbs vertical force on Wii platform;   American Orthopaedic Foot and Ankle Scale (AOFAS);   36-Item Short Form Health Survey (SF-36)
2 Recruiting Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
Condition: Mesothelioma
Intervention: Drug: Zometa (zoledronic acid)
Outcome Measures: Evaluation of the tumor response rate following zoledronic acid;   Evaluation of the duration of tumor response
3 Recruiting Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   Invasive Ductal Breast Carcinoma;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer
Interventions: Drug: zoledronic acid;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
Outcome Measures: Changes in biomarkers of tumor growth and metastasis in women with newly diagnosed ER and/or PR positive invasive ductal breast cancer receiving zoledronic acid;   Changes in immunologic function after a single dose of zoledronic acid;   Changes in the expression of tumor markers important to breast cancer progression and metastasis in women receiving zoledronic acid
4 Recruiting Zoledronic Acid in Acute Spinal Cord Injury
Condition: Complete Traumatic Spinal Cord Injury
Interventions: Drug: Zoledronic acid;   Drug: normal saline 0.9%
Outcome Measures: change in bone mineral density;   Biomarkers of bone formation and resorption;   safety and tolerability of zoledronic acid
5 Unknown  Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma
Condition: Osteosarcoma
Interventions: Drug: Zoledronic acid;   Drug: Standard chemotherapy
Outcome Measure: histological response disease free interval
6 Recruiting The Effect of Treatment With Teriparatide and Zoledronic Acid in Patients With Osteogenesis Imperfecta
Condition: Osteogenesis Imperfecta
Interventions: Drug: Zoledronic acid;   Drug: Teriparatide;   Drug: placebo zoledronic acid;   Drug: placebo teriparatide
Outcome Measures: Bone Mineral Density (BMD);   Fracture risk
7 Recruiting Bone Loss Treatment From Adjuvant Zoledronate Efficacy
Conditions: Breast Neoplasms;   Bone Loss
Intervention: Drug: Zoledronate
Outcome Measures: Change from Baseline in Bone Mineral Density;   Bone metastasis rate;   Disease-Free Survival
8 Recruiting Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Subjects With Multiple Myeloma
Conditions: Cancer;   Hematologic Malignancies;   Multiple Myeloma;   Oncology;   Bone Metastases;   Multiple Myeloma Bone Lesions
Interventions: Drug: Denosumab;   Drug: Zoledronic acid
Outcome Measures: Time to the first on-study skeletal related event (SRE) (non-inferiority test);   Time to the first-and-subsequent SRE (superiority test, using multiple event analysis);   Time to the first on-study SRE (superiority test)
9 Recruiting Effect of the Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Who Have Relapsed After 1-3 Prior Lines of Therapy
Condition: Multiple Myeloma
Interventions: Drug: Bortezomib;   Drug: Zoledronic Acid;   Drug: Dexamethasone
Outcome Measures: Bone Mineral Density (BMD);   Bone mineral density (BMD);   Serum values of bone-specific alkaline phosphatase, osteocalcin and C-terminal cross-linking telopeptides of collagen type-I;   Bone pain;   Skeletal-related events (SRE: pathologic fractures, need for bone radiation therapy or surgery);   Improvement of osteolytic lesions
10 Not yet recruiting Genetics in Predicting Risk of Bisphosphonate-Related Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid
Conditions: Malignant Neoplasm;   Musculoskeletal Complications
Interventions: Drug: zoledronic acid;   Other: pharmacological study
Outcome Measures: Plasma concentrations of Zol collected at visits 2, 3, 4, and 5;   Urine concentrations of Zol collected at visits 2, 3, 4, and 5;   Jawbone tissue concentrations of Zol collected during surgical treatment for BRONJ;   Identify potential risk factors for BRONJ
11 Recruiting Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Zoledronic Acid;   Biological: Aldesleukin
Outcome Measures: Evaluate the safety and toxicity of zoledronic acid and aldesleukin;   Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin;   uoEvaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells;   To document tumor response in patients with measurable disease.;   Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available.
12 Recruiting The ODYSSEY TRIAL Phase IV Trial Evaluating the Palliative Benefit of Pamidronate or Zoledronic Acid in Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Pamidronate;   Drug: Zoledronic acid;   Drug: placebo
Outcome Measures: sCTX values;   Palliative response
13 Recruiting Adjuvant Zoledronic Acid in High Risk Giant Cell Tumour of Bone (GCT)
Conditions: Giant Cell Tumor of Bone;   Osteoclastoma
Intervention: Drug: Zoledronic acid
Outcome Measures: Determine if adjuvant zoledronic acid improves the 2 year recurrence rate of 'high risk' GCT as compared to standard care;   Evaluate the usefulness of bone remodelling markers in diagnosing and monitoring GCT;   Determine the relapse free survival
14 Recruiting N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
Condition: Neuroblastoma
Interventions: Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
Outcome Measures: Determination of toxicities and feasibility of the combination of bolus plus metronomic cyclophosphamide and zoledronic acid with and without bevacizumab when given to children with refractory or recurrent high risk neuroblastoma.;   Evaluation of response within the confines of a phase I study.;   Analysis of Circulating Endothelial Cells, Circulating Factors, Gene expression and Bone Metabolism Studies.
15 Recruiting FES-Rowing Versus Zoledronic Acid to Improve Bone Health in Spinal Cord Injury (SCI)
Condition: Osteoporosis
Interventions: Other: FES-Rowing;   Drug: Zoledronic acid
Outcome Measures: Improvement of bone mass as measured by sequential evaluation of bone density and bone structure;   Validation of DXA Scanning in patients with SCI
16 Recruiting 1 Year Open-label Extension to CZOL446H2337 Safety and Efficacy Trial of Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids for Chronic Inflammatory Conditions
Condition: Osteoporosis
Intervention: Drug: zoledronic acid
Outcome Measures: Safety of zoledronic acid for the treatment of osteoporotic children treated with glucocorticoids for chronic inflammatory conditions by adverse event collection and laboratory results monitoring.;   Change from baseline in LS areal BMD Z-score at Month 18 and 24 by core treatment group by dual energy x-ray absorptiometry (DXA).;   Change from baseline in LS and total body BMC by core treatment group by DXA.;   Change in biochemical marker values (serum P1NP, BSAP, NTx and TRAP-5b) from baseline.;   Change in the number of new clinical vertebral fractures and new morphometric vertebral fractures.;   To evaluate the change from baseline (Visit 1 of the Core study) in pain using the Faces Pain Scale-Revised (FPS-R)by core treatment group.
17 Unknown  Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Sorafenib and Zoledronic Acid
Outcome Measures: numbers of adverse events;   Overall survival (OS), time to progression (TTP)
18 Recruiting Research of Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy to Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Zoledronic Acid and Aromatase Inhibitors
Outcome Measures: therapeutic assessment;   Adverse reactions and disease-free survival
19 Recruiting HOBOE: A Phase 3 Study of Adjuvant Triptorelin and Tamoxifen, Letrozole, or Letrozole and Zoledronic Acid in Premenopausal Patients With Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: tamoxifen;   Drug: triptorelin;   Drug: letrozole;   Drug: zoledronic acid
Outcome Measures: disease free survival in premenopausal patients;   bone mineral density;   Bone mineral density measured;   disease free survival in postmenopausal patients;   overall survival;   toxicity of letrozole + triptorelin and letrozole + zoledronic acid + triptorelin in premenopausal patients
20 Not yet recruiting Zoledronic Acid in Rheumatoid Arthritis
Condition: Arthritis, Rheumatoid
Intervention: Drug: Zoledronic acid
Outcome Measure: Sharp van der Heijde index